Mesothelin as a target for chimeric antigen receptor-modified T cells as anticancer therapy

Immunotherapy

Volumn 8, Issue 4, 2016, Pages 449-460

  O'Hara, Mark ^a   Stashwick, Caitlin ^a   Haas, Andrew R ^a   Tanyi, Janos L ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

chimeric antigen receptor; immunotherapy; mesothelin; mesothelioma; ovarian cancer; pancreatic cancer

Indexed keywords

AMATUXIMAB; ANETUMAB RAVTANSINE; ANTINEOPLASTIC AGENT; CANCER VACCINE; CHIMERIC ANTIGEN RECEPTOR; CISPLATIN; CRS 207; CYCLOPHOSPHAMIDE; DNA VACCINE; DRUG ANTIBODY; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; IMMUNOMODULATING AGENT; IMMUNOTOXIN; LENTIVIRUS VECTOR; MESOTHELIN; MESSENGER RNA; PEMETREXED; PENTOSTATIN; PLACEBO; SS1P COMPLEX; UNCLASSIFIED DRUG; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; HYBRID PROTEIN; LYMPHOCYTE ANTIGEN RECEPTOR;

CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER THERAPY; CELL THERAPY; CLINICAL EVALUATION; CLINICAL TRIAL (TOPIC); DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; FEVER; GENE EXPRESSION; HUMAN; HYPERTRANSAMINASEMIA; HYPOPHOSPHATEMIA; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; LENTIVIRINAE; LYMPHOCYTOPENIA; MESOTHELIOMA; MOLECULARLY TARGETED THERAPY; NEOPLASM; NONHUMAN; OVARY CANCER; OVARY CARCINOMA; PANCREAS ADENOCARCINOMA; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; SERUM SICKNESS; SOLID TUMOR; T LYMPHOCYTE; THROMBOEMBOLISM; VIRAL GENE DELIVERY SYSTEM; ADOPTIVE IMMUNOTHERAPY; ANIMAL; FEMALE; GENETICS; IMMUNOLOGY; OVARIAN NEOPLASMS; PANCREATIC NEOPLASMS; PHYSIOLOGY; TRANSPLANTATION;

ANIMALS; CANCER VACCINES; CLINICAL TRIALS AS TOPIC; FEMALE; GPI-LINKED PROTEINS; HUMANS; IMMUNOTHERAPY, ADOPTIVE; MESOTHELIOMA; MOLECULAR TARGETED THERAPY; OVARIAN NEOPLASMS; PANCREATIC NEOPLASMS; RECEPTORS, ANTIGEN, T-CELL; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES;

EID: 84962564789     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.16.4     Document Type: Review

References (101)

1. Maude SL, Frey N, Shaw PA, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N. Engl. J. Med. 371(16), 1507-1517 (2014).
2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J. Clin. 65(1), 5-29 (2015).
3. Lovly CM, Shaw AT. Molecular pathways: resistance to kinase inhibitors and implications for therapeutic strategies. Clin. Cancer Res. 20(9), 2249-2256 (2014).
4. Pennock GK, Chow LQ. The evolving role of immune checkpoint inhibitors in cancer treatment. Oncologist 20(7), 812-822 (2015).
5. Chang K, Pai LH, Batra JK, Pastan I, Willingham MC. Characterization of the antigen (CAK1) recognized by monoclonal antibody K1 present on ovarian cancers and normal mesothelium. Cancer Res. 52(1), 181-186 (1992).
6. Chang K, Pastan I. Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. Proc. Natl Acad. Sci. USA 93(1), 136-140 (1996).
7. Yamaguchi N, Hattori K, Oh-Eda M, Kojima T, Imai N, Ochi N. A novel cytokine exhibiting megakaryocyte potentiating activity from a human pancreatic tumor cell line HPC-Y5. J. Biol. Chem. 269(2), 805-808 (1994).
8. Chang K, Pastan I, Willingham MC. Isolation and characterization of a monoclonal antibody, K1, reactive with ovarian cancers and normal mesothelium. Int. J. Cancer 50(3), 373-381 (1992).
9. Jirsova K, Neuwirth A, Kalasova S, Vesela V, Merjava S. Mesothelial proteins are expressed in the human cornea. Exp. Eye Res. 91(5), 623-629 (2010).
10. Rump A, Morikawa Y, Tanaka M, et al. Binding of ovarian cancer antigen CA125/MUC16 to mesothelin mediates cell adhesion. J. Biol. Chem. 279(10), 9190-9198 (2004).
11. Bera TK, Pastan I. Mesothelin is not required for normal mouse development or reproduction. Mol. Cell. Biol. 20(8), 2902-2906 (2000).
12. Pastan I, Hassan R. Discovery of mesothelin and exploiting it as a target for immunotherapy. Cancer Res. 74(11), 2907-2912 (2014).
13. Chang K, Pai LH, Pass H, et al. Monoclonal antibody K1 reacts with epithelial mesothelioma but not with lung adenocarcinoma. Am. J. Surg. Pathol. 16(3), 259-268 (1992).
14. Ordonez NG. Application of mesothelin immunostaining in tumor diagnosis. Am. J. Surg. Pathol. 27(11), 1418-1428 (2003).
15. Argani P, Iacobuzio-Donahue C, Ryu B, et al. Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE). Clin. Cancer Res. 7(12), 3862-3868 (2001).
16. Chang K, Pastan I, Willingham MC. Frequent expression of the tumor antigen CAK1 in squamous-cell carcinomas. Int. J. Cancer 51(4), 548-554 (1992).
17. Miettinen M, Sarlomo-Rikala M. Expression of calretinin, thrombomodulin, keratin 5, and mesothelin in lung carcinomas of different types: an immunohistochemical analysis of 596 tumors in comparison with epithelioid mesotheliomas of the pleura. Am. J. Surg. Pathol. 27(2), 150-158 (2003).
18. Tchou J, Wang LC, Selven B, et al. Mesothelin, a novel immunotherapy target for triple negative breast cancer. Breast Cancer Res. Treat. 133(2), 799-804 (2012).
19. Ren YR, Patel K, Paun BC, Kern SE. Structural analysis of the cancer-specific promoter in mesothelin and in other genes overexpressed in cancers. J. Biol. Chem. 286(14), 11960-11969 (2011).
20. Kachala SS, Bograd AJ, Villena-Vargas J, et al. Mesothelin overexpression is a marker of tumor aggressiveness and is associated with reduced recurrence-free and overall survival in early-stage lung adenocarcinoma. Clin. Cancer Res. 20(4), 1020-1028 (2014).
21. Thomas A, Chen Y, Steinberg SM, et al. High mesothelin expression in advanced lung adenocarcinoma is associated with KRAS mutations and a poor prognosis. Oncotarget 6(13), 11694-11703 (2015).
22. Tozbikian G, Brogi E, Kadota K, et al. Mesothelin expression in triple negative breast carcinomas correlates significantly with basal-like phenotype, distant metastases and decreased survival. PLoS One 9(12), e114900 (2014).
23. Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 74(11), 2913-2921 (2014).
24. Hassan R, Laszik ZG, Lerner M, Raffeld M, Postier R, Brackett D. Mesothelin is overexpressed in pancreaticobiliary adenocarcinomas but not in normal pancreas and chronic pancreatitis. Am. J. Clin. Pathol. 124(6), 838-845 (2005).
25. Thomas AM, Santarsiero LM, Lutz ER, et al. Mesothelin-specific CD8(+) T cell responses provide evidence of in vivo cross-priming by antigen-presenting cells in vaccinated pancreatic cancer patients. J. Exp. Med. 200(3), 297-306 (2004).
26. Chen Y, Ayaru L, Mathew S, Morris E, Pereira SP, Behboudi S. Expansion of anti-mesothelin specific CD4+ and CD8+ T cell responses in patients with pancreatic carcinoma. PLoS One 9(2), e88133 (2014).
27. Einama T, Kamachi H, Nishihara H, et al. Co-Expression of mesothelin and CA125 correlates with unfavorable patient outcome in pancreatic ductal adenocarcinoma. Pancreas 40(8), 1276-1282 (2011).
28. Shimizu A, Hirono S, Tani M, et al. Coexpression of MUC16 and mesothelin is related to the invasion process in pancreatic ductal adenocarcinoma. Cancer Sci. 103(4), 739-746 (2012).
29. Zheng C, Jia W, Tang Y, Zhao H, Jiang Y, Sun S. Mesothelin regulates growth and apoptosis in pancreatic cancer cells through p53-Dependent and-independent signal pathway. J. Exp. Clin. Cancer Res. doi: 10.1186/1756-9966-31-84 (2012) (Epub ahead of print).
30. Chen SH, Hung WC, Wang P, Paul C, Konstantopoulos K. Mesothelin binding to CA125/MUC16 promotes pancreatic cancer cell motility and invasion via MMP-7 activation. Sci. Rep. 3, Article number: 1870, doi: 10.1038/srep01870 (2013).
31. Kim A, Ueda Y, Naka T, Enomoto T. Therapeutic strategies in epithelial ovarian cancer. J. Exp. Clin. Cancer Res. doi: 10.1186/1756-9966-31-14 (2012) (Epub ahead of print).
32. Rubin SC, Randall TC, Armstrong KA, Chi DS, Hoskins WJ. Ten-year follow-up of ovarian cancer patients after second-look laparotomy with negative findings. Obstet. Gynecol. 93(1), 21-24 (1999).
33. Hassan R, Kreitman RJ, Pastan I, Willingham MC. Localization of mesothelin in epithelial ovarian cancer. Appl. Immunohistochem. Mol. Morphol. 13(3), 243-247 (2005).
34. Gubbels JA, Belisle J, Onda M, et al. Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors. Mol. Cancer 5(1), 50 (2006).
35. Fujita K, Ikarashi H, Takakuwa K, et al. Prolonged disease-free period in patients with advanced epithelial ovarian cancer after adoptive transfer of tumor-infiltrating lymphocytes. Clin. Cancer Res. 1(5), 501-507 (1995).
36. Zhang L, Conejo-Garcia JR, Katsaros D, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N. Engl. J. Med. 348(3), 203-213 (2003).
37. Hwang WT, Adams SF, Tahirovic E, Hagemann IS, Coukos G. Prognostic significance of tumor-infiltrating T cells in ovarian cancer: a meta-Analysis. Gynecol. Oncol. 124(2), 192-198 (2012).
38. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J. Clin. Oncol. 21(14), 2636-2644 (2003).
39. Ordonez NG. Value of mesothelin immunostaining in the diagnosis of mesothelioma. Mod. Pathol. 16(3), 192-197 (2003).
40. Servais EL, Colovos C, Rodriguez L, et al. Mesothelin overexpression promotes mesothelioma cell invasion and MMP-9 secretion in an orthotopic mouse model and in epithelioid pleural mesothelioma patients. Clin. Cancer Res. 18(9), 2478-2489 (2012).
41. Hassan R, Bullock S, Premkumar A, et al. Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-Expressing mesothelioma, ovarian, and pancreatic cancers. Clin. Cancer Res. 13(17), 5144-5149 (2007).
42. Kreitman RJ, Hassan R, Fitzgerald DJ, Pastan I. Phase I trial of continuous infusion anti-mesothelin recombinant immunotoxin SS1P. Clin. Cancer Res. 15(16), 5274-5279 (2009).
43. Hassan R, Miller AC, Sharon E, et al. Major cancer regressions in mesothelioma after treatment with an anti-mesothelin immunotoxin and immune suppression. Sci. Transl. Med. 5(208), 208ra147 (2013).
44. Hassan R, Sharon E, Thomas A, et al. Phase 1 study of the antimesothelin immunotoxin SS1P in combination with pemetrexed and cisplatin for front-line therapy of pleural mesothelioma and correlation of tumor response with serum mesothelin, megakaryocyte potentiating factor, and cancer antigen 125. Cancer 120(21), 3311-3319 (2014).
45. Hassan R, Cohen SJ, Phillips M, et al. Phase I clinical trial of the chimeric anti-mesothelin monoclonal antibody MORAb-009 in patients with mesothelin-Expressing cancers. Clin. Cancer Res. 16(24), 6132-6138 (2010).
46. Hassan R, Kindler HL, Jahan T, et al. Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma. Clin. Cancer Res. 20(23), 5927-5936 (2014).
47. Le DT, Brockstedt DG, Nir-Paz R, et al. A live-Attenuated Listeria vaccine (ANZ-100) and a live-Attenuated Listeria vaccine expressing mesothelin (CRS-207) for advanced cancers: Phase I studies of safety and immune induction. Clin. Cancer Res. 18(3), 858-868 (2012).
48. Le DT, Wang-Gillam A, Picozzi V, et al. Safety and survival with GVAX pancreas prime and Listeria Monocytogenes-Expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer. J. Clin. Oncol. 33(12), 1325-1333 (2015).
49. Bendell J, Blumenschein G, Zinner R, et al. Abstract LB-291: First-in-human Phase I dose escalation study of a novel anti-mesothelin antibody drug conjugate (ADC), BAY 94-9343, in patients with advanced solid tumors. Cancer Res. 73(8 Supplement), LB-291 (2013).
50. Jaffee EM, Schutte M, Gossett J, et al. Development and characterization of a cytokine-secreting pancreatic adenocarcinoma vaccine from primary tumors for use in clinical trials. Cancer J. Sci. Am. 4(3), 194-203 (1998).
51. Jaffee EM, Hruban RH, Biedrzycki B, et al. Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a Phase I trial of safety and immune activation. J. Clin. Oncol. 19(1), 145-156 (2001).
52. Laheru D, Lutz E, Burke J, et al. Allogeneic granulocyte macrophage colony-stimulating factor-secreting tumor immunotherapy alone or in sequence with cyclophosphamide for metastatic pancreatic cancer: a pilot study of safety, feasibility, and immune activation. Clin. Cancer Res. 14(5), 1455-1463 (2008).
53. Lutz E, Yeo CJ, Lillemoe KD, et al. A lethally irradiated allogeneic granulocyte-macrophage colony stimulating factor-secreting tumor vaccine for pancreatic adenocarcinoma. A Phase II trial of safety, efficacy, and immune activation. Ann. Surg. 253(2), 328-335 (2011).
54. Le DT, Lutz E, Uram JN, et al. Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer. J. Immunother. 36(7), 382-389 (2013).
55. Golfier S, Kopitz C, Kahnert A, et al. Anetumab ravtansine: a novel mesothelin-Targeting antibody-Drug conjugate cures tumors with heterogeneous target expression favored by bystander effect. Mol. Cancer Ther. 13(6), 1537-1548 (2014).
56. Carpenito C, Milone MC, Hassan R, et al. Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. Proc. Natl Acad. Sci. USA 106(9), 3360-3365 (2009).
57. Lanitis E, Poussin M, Hagemann IS, et al. Redirected antitumor activity of primary human lymphocytes transduced with a fully human anti-mesothelin chimeric receptor. Mol. Ther. 20(3), 633-643 (2012).
58. Zhao Y, Moon E, Carpenito C, et al. Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor. Cancer Res. 70(22), 9053-9061 (2010).
59. Beatty GL, Haas AR, Maus MV, et al. Mesothelin-specific chimeric antigen receptor mRNA-Engineered T cells induce anti-Tumor activity in solid malignancies. Cancer Immunol. Res. 2(2), 112-120 (2014).
60. Brocker T, Karjalainen K. Signals through T cell receptor-zeta chain alone are insufficient to prime resting T lymphocytes. J. Exp. Med. 181(5), 1653-1659 (1995).
61. Cooper LJ, Topp MS, Serrano LM, et al. T-cell clones can be rendered specific for CD19: toward the selective augmentation of the graft-versus-B-lineage leukemia effect. Blood 101(4), 1637-1644 (2003).
62. Brentjens RJ, Latouche JB, Santos E, et al. Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15. Nat. Med. 9(3), 279-286 (2003).
63. Kershaw MH, Westwood JA, Parker LL, et al. A Phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin. Cancer Res. 12(20 Pt 1), 6106-6115 (2006).
64. Brentjens RJ, Santos E, Nikhamin Y, et al. Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts. Clin. Cancer Res. 13(18 Pt 1), 5426-5435 (2007).
65. Park JR, Digiusto DL, Slovak M, et al. Adoptive transfer of chimeric antigen receptor re-Directed cytolytic T lymphocyte clones in patients with neuroblastoma. Mol. Ther. 15(4), 825-833 (2007).
66. Lamers CH, Willemsen R, Van Elzakker P, et al. Immune responses to transgene and retroviral vector in patients treated with ex vivo-Engineered T cells. Blood 117(1), 72-82 (2011).
67. Bretscher P, Cohn M. A theory of self-nonself discrimination. Science 169(3950), 1042-1049 (1970).
68. Brocker T. Chimeric Fv-zeta or Fv-Epsilon receptors are not sufficient to induce activation or cytokine production in peripheral T cells. Blood 96(5), 1999-2001 (2000).
69. Imai C, Mihara K, Andreansky M, et al. Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia. Leukemia 18(4), 676-684 (2004).
70. Maher J, Brentjens RJ, Gunset G, Riviere I, Sadelain M. Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta/CD28 receptor. Nat. Biotechnol. 20(1), 70-75 (2002).
71. Finney HM, Akbar AN, Lawson AD. Activation of resting human primary T cells with chimeric receptors: costimulation from CD28, inducible costimulator, CD134, and CD137 in series with signals from the TCR zeta chain. J. Immunol. 172(1), 104-113 (2004).
72. Milone MC, Fish JD, Carpenito C, et al. Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. Mol. Ther. 17(8), 1453-1464 (2009).
73. Song DG, Ye Q, Poussin M, Harms GM, Figini M, Powell DJ, Jr. CD27 costimulation augments the survival and antitumor activity of redirected human T cells in vivo. Blood 119(3), 696-706 (2012).
74. Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N. Engl. J. Med. 365(8), 725-733 (2011).
75. Kochenderfer JN, Dudley ME, Kassim SH, et al. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J. Clin. Oncol. 33(6), 540-549 (2015).
76. Wang J, Jensen M, Lin Y, et al. Optimizing adoptive polyclonal T cell immunotherapy of lymphomas, using a chimeric T cell receptor possessing CD28 and CD137 costimulatory domains. Hum. Gene Ther. 18(8), 712-725 (2007).
77. Zhong XS, Matsushita M, Plotkin J, Riviere I, Sadelain M. Chimeric antigen receptors combining 4-1BB and CD28 signaling domains augment PI3kinase/AKT/Bcl-XL activation and CD8+ T cell-mediated tumor eradication. Mol. Ther. 18(2), 413-420 (2010).
78. Choi BD, Suryadevara CM, Gedeon PC, et al. Intracerebral delivery of a third generation EGFRvIII-specific chimeric antigen receptor is efficacious against human glioma. J. Clin. Neurosci. 21(1), 189-190 (2014).
79. Till BG, Jensen MC, Wang J, et al. CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results. Blood 119(17), 3940-3950 (2012).
80. Lamers CH, Sleijfer S, Vulto AG, et al. Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. J. Clin. Oncol. 24(13), e20-E22 (2006).
81. Lamers CH, Sleijfer S, Van Steenbergen S, et al. Treatment of metastatic renal cell carcinoma with CAIX CAR-Engineered T cells: clinical evaluation and management of on-Target toxicity. Mol. Ther. 21(4), 904-912 (2013).
82. Hacein-Bey-Abina S, Garrigue A, Wang GP, et al. Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J. Clin. Invest. 118(9), 3132-3142 (2008).
83. Zhao Y, Zheng Z, Cohen CJ, et al. High-Efficiency transfection of primary human and mouse T lymphocytes using RNA electroporation. Mol. Ther. 13(1), 151-159 (2006).
84. Barrett DM, Zhao Y, Liu X, et al. Treatment of advanced leukemia in mice with mRNA engineered T cells. Hum. Gene Ther. 22(12), 1575-1586 (2011).
85. Barrett DM, Liu X, Jiang S, June CH, Grupp SA, Zhao Y. Regimen-specific effects of RNA-modified chimeric antigen receptor T cells in mice with advanced leukemia. Hum. Gene Ther. 24(8), 717-727 (2013).
86. Kenderian SS, Ruella M, Shestova O, et al. CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia. Leukemia 29(8), 1637-1647 (2015).
87. Beatty GL, O'Hara MH, Nelson AM, et al. Safety and antitumor activity of chimeric antigen receptor modified T cells in patients with chemotherapy refractory metastatic pancreatic cancer. ASCO Meeting Abstracts 33(15 Suppl.), 3007 (2015).
88. Naldini L, Blomer U, Gallay P, et al. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 272(5259), 263-267 (1996).
89. Levine BL, Mosca JD, Riley JL, et al. Antiviral effect and ex vivo CD4+ T cell proliferation in HIV-positive patients as a result of CD28 costimulation. Science 272(5270), 1939-1943 (1996).
90. Levine BL, Humeau LM, Boyer J, et al. Gene transfer in humans using a conditionally replicating lentiviral vector. Proc. Natl Acad. Sci. USA 103(46), 17372-17377 (2006).
91. Bobisse S, Rondina M, Merlo A, et al. Reprogramming T lymphocytes for melanoma adoptive immunotherapy by T-cell receptor gene transfer with lentiviral vectors. Cancer Res. 69(24), 9385-9394 (2009).
92. Kalos M, Levine BL, Porter DL, et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci. Transl. Med. 3(95), 95ra73 (2011).
93. Grupp SA, Kalos M, Barrett D, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N. Engl. J. Med. 368(16), 1509-1518 (2013).
94. Moon EK, Wang LC, Dolfi DV, et al. Multifactorial T-cell hypofunction that is reversible can limit the efficacy of chimeric antigen receptor-Transduced human T cells in solid tumors. Clin. Cancer Res. 20(16), 4262-4273 (2014).
95. Adusumilli PS, Cherkassky L, Villena-Vargas J, et al. Regional delivery of mesothelin-Targeted CAR T cell therapy generates potent and long-lasting CD4-Dependent tumor immunity. Sci. Transl. Med. 6(261), 261ra151 (2014).
96. Beatty GL, Moon EK. Chimeric antigen receptor T cells are vulnerable to immunosuppressive mechanisms present within the tumor microenvironment. Oncoimmunology 3(11), e970027 (2014).
97. Maus MV, Haas AR, Beatty GL, et al. T cells expressing chimeric antigen receptors can cause anaphylaxis in humans. Cancer Immunol. Res.1(1), 26-31(2013).
98. Budde LE, Berger C, Lin Y, et al. Combining a CD20 chimeric antigen receptor and an inducible caspase 9 suicide switch to improve the efficacy and safety of T cell adoptive immunotherapy for lymphoma. PLoS One 8(12), e82742 (2013).
99. Jones BS, Lamb LS, Goldman F, Di Stasi A. Improving the safety of cell therapy products by suicide gene transfer. Front. Pharmacol.doi: 10.3389/fphar.2014.00254 (2014) (Epub ahead of print).
100. Kieback E, Charo J, Sommermeyer D, Blankenstein T, Uckert W. A safeguard eliminates T cell receptor gene-modified autoreactive T cells after adoptive transfer. Proc. Natl Acad. Sci. USA 105(2), 623-628 (2008).
101. Tanyi J, Haas A, Beatty G, et al. Safety and feasibility of chimeric antigen receptor modified T cells directed against mesothelin (CART-meso) in patients with mesothelin-Expressing cancers. Presented at: American Association for Cancer Research Annual Meeting. PA, USA 18-22 April 2015.